SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Stereotaxis, Inc. (STXS) (CIK 0001289340) (STXS) — Oct 1, 2019

Stereotaxis, Inc. (STXS) (CIK 0001289340)
Date: Oct. 1, 2019 · CIK: 0001289340 · Accession: 0000000000-19-014110

Regulatory Compliance Offering / Registration Process Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-233846

Date
September 30, 2019
Author
David L. Fischel
Form
UPLOAD
Company
Stereotaxis, Inc. (STXS) (CIK 0001289340)

Letter

September 30, 2019 David L. Fischel Chief Executive Officer Stereotaxis, Inc. 4320 Forest Park Avenue, Suite 100 St. Louis, Missouri 63108 Re:Stereotaxis, Inc. Registration Statement on Form S-3 Filed September 19, 2019 File No. 333-233846 Dear Mr. Fischel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance CF Office of Life Sciences cc: Robert J. Endicott, Esq.

Show Raw Text
September 30, 2019
David L. Fischel
Chief Executive Officer
Stereotaxis, Inc.
4320 Forest Park Avenue, Suite 100
St. Louis, Missouri 63108
Re:Stereotaxis, Inc.
Registration Statement on Form S-3
Filed September 19, 2019
File No. 333-233846
Dear Mr. Fischel:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
CF Office of Life Sciences
cc:       Robert J. Endicott, Esq.